Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Haematologica- Italy

doi 10.3324/haematol.2015.131144

Full Text

Abstract

Available in

Date

August 6, 2015

Authors

Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia

English

A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis

Hematological Oncology

English

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy

American Journal of Hematology

Hematology

2017

English

Treatment With Combination of Lenalidomide and Rituximab Achieves Durable Responses in a Long Term Follow Up of Patients With Indolent Non-Hodgkin's Lymphoma

Hematological Oncology

English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma

English

A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma

British Journal of Haematology

Hematology

2015

English

Pegfilgrastim in Primary Prophylaxis of Febrile Neutropenia Following Frontline Bendamustine Plus Rituximab Treatment in Patients With Indolent Non-Hodgkin Lymphoma: A Single Center, Real-Life Experience

Supportive Care in Cancer

Oncology

2016

English

Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab

British Journal of Haematology

Hematology

2018

English

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Advances in Hematology

Hematology

2012

English

Amanote Research

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Haematologica- Italy

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy

Treatment With Combination of Lenalidomide and Rituximab Achieves Durable Responses in a Long Term Follow Up of Patients With Indolent Non-Hodgkin's Lymphoma

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Pegfilgrastim in Primary Prophylaxis of Febrile Neutropenia Following Frontline Bendamustine Plus Rituximab Treatment in Patients With Indolent Non-Hodgkin Lymphoma: A Single Center, Real-Life Experience

Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas